More articles from Article

Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells
Hiroji Uemura, Hitoshi Ishiguro, Yoji Nagashima, Takeshi Sasaki, Noboru Nakaigawa, Hisashi Hasumi, Shingo Kato, Yoshinobu Kubota

Molecular Cancer Therapeutics Nov 2005, 4 (11) 1699-1709; DOI: 10.1158/1535-7163.MCT-04-0295
Biological and molecular properties of a new α_vβ₃/α_vβ₅ integrin antagonist
Laura Belvisi, Teresa Riccioni, Marcella Marcellini, Loredana Vesci, Ilaria Chiarucci, Daniela Efrati, Donatella Potenza, Carlo Scolastico, Leonardo Manzoni, Katia Lombardo, M. Antonietta Stasi, Augusto Orlandi, Alessandro Ciucci, Beatrice Nico, Domenico Ribatti, Giuseppe Giannini, Marco Presta, Paolo Carminati, Claudio Pisano

Molecular Cancer Therapeutics Nov 2005, 4 (11) 1670-1680; DOI: 10.1158/1535-7163.MCT-05-0120
Gene therapy with E2F-1 up-regulates the protein kinase PKR and inhibits growth of leiomyosarcoma in vivo
Stephan A. Vorburger, Nophadol Hetrakul, Weiya Xia, Marcia Wilson-Heiner, Nadeem Mirza, Raphael E. Pollock, Barry Feig, Stephen G. Swisher, Kelly K. Hunt

Molecular Cancer Therapeutics Nov 2005, 4 (11) 1710-1716; DOI: 10.1158/1535-7163.MCT-05-0036
Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells
Roohangiz Safaei, Barrett J. Larson, Timothy C. Cheng, Michael A. Gibson, Shinji Otani, Wiltrud Naerdemann, Stephen B. Howell

Molecular Cancer Therapeutics Oct 2005, 4 (10) 1595-1604; DOI: 10.1158/1535-7163.MCT-05-0102
Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells
David Peters, John Freund, Robert L. Ochs

Molecular Cancer Therapeutics Oct 2005, 4 (10) 1605-1616; DOI: 10.1158/1535-7163.MCT-04-0311
WMC-79, a potent agent against colon cancers, induces apoptosis through a p53-dependent pathway
Teresa Kosakowska-Cholody, W. Marek Cholody, Anne Monks, Barbara A. Woynarowska, Christopher J. Michejda

Molecular Cancer Therapeutics Oct 2005, 4 (10) 1617-1627; DOI: 10.1158/1535-7163.MCT-05-0170
YC-1 suppresses constitutive nuclear factor-κB activation and induces apoptosis in human prostate cancer cells
Yao-Ting Huang, Shiow-Lin Pan, Jih-Hwa Guh, Ya-Ling Chang, Fang-Yu Lee, Sheng-Chu Kuo, Che-Ming Teng

Molecular Cancer Therapeutics Oct 2005, 4 (10) 1628-1635; DOI: 10.1158/1535-7163.MCT-05-0090
Radiosensitization of MDA-MB-231 breast tumor cells by adenovirus-mediated overexpression of a fragment of the XRCC4 protein
Kara R. Jones, David A. Gewirtz, Steven M. Yannone, Shaoming Zhou, David G. Schatz, Kristoffer Valerie, Lawrence F. Povirk

Molecular Cancer Therapeutics Oct 2005, 4 (10) 1541-1547; DOI: 10.1158/1535-7163.MCT-05-0193
Role of p21^waf1/cip1 in effects of oxaliplatin in colorectal cancer cells
Taishi Hata, Hirofumi Yamamoto, Chew Yee Ngan, Minoru Koi, Akimitsu Takagi, Bazarragchaa Damdinsuren, Masayoshi Yasui, Yujiro Fujie, Takeshi Matsuzaki, Hiromichi Hemmi, Xundi Xu, Kotaro Kitani, Yosuke Seki, Ichiro Takemasa, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsuura, Morito Monden

Molecular Cancer Therapeutics Oct 2005, 4 (10) 1585-1594; DOI: 10.1158/1535-7163.MCT-05-0011
Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells
David L. Morse, Heather Gray, Claire M. Payne, Robert J. Gillies

Molecular Cancer Therapeutics Oct 2005, 4 (10) 1495-1504; DOI: 10.1158/1535-7163.MCT-05-0130

Main menu

User menu

Search

More articles from Article

Pages

Articles

Info for

About MCT